<code id='517B0742B2'></code><style id='517B0742B2'></style>
    • <acronym id='517B0742B2'></acronym>
      <center id='517B0742B2'><center id='517B0742B2'><tfoot id='517B0742B2'></tfoot></center><abbr id='517B0742B2'><dir id='517B0742B2'><tfoot id='517B0742B2'></tfoot><noframes id='517B0742B2'>

    • <optgroup id='517B0742B2'><strike id='517B0742B2'><sup id='517B0742B2'></sup></strike><code id='517B0742B2'></code></optgroup>
        1. <b id='517B0742B2'><label id='517B0742B2'><select id='517B0742B2'><dt id='517B0742B2'><span id='517B0742B2'></span></dt></select></label></b><u id='517B0742B2'></u>
          <i id='517B0742B2'><strike id='517B0742B2'><tt id='517B0742B2'><pre id='517B0742B2'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:689
          An FDA sign — health policy coverage from STAT
          Sarah Silbiger/Getty Images

          WASHINGTON — There’s about to be a new acronym in town.

          The Food and Drug Administration is in the final stages of cementing sweeping changes to the Office of Regulatory Affairs, which oversees inspections and compliance for all its regulated products, according to three people familiar with the planning.

          advertisement

          That overhaul includes a new name: Meet the Office of Inspections and Investigations.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          More tobacco lobbyists active in statehouses
          More tobacco lobbyists active in statehouses

          NathanHoward/GettyImagesWASHINGTON—Aroundthecountry,statehousesfromHarrisburg,Pa.,toTallahassee,Fla.

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

          AdobeWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiotechnewsletterinyo